Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Genomic Health, TriPath Imaging, Bio-Reference Labs, Canadian Patient Registry

PREDICTIVE TESTING FOR RECURRENT BREAST CANCER LABORATORY TESTS DESIGNED to predict the recurrence of breast cancer are picking up momentum. First to market was Genomic Health Inc.’s Oncotype DX™ breast cancer test. Now TriPath Imaging, Inc. is reporting favorable results from studies of its ProEx Br markers for breast cancer. Since introducing Oncotype DX in …

Genomic Health, TriPath Imaging, Bio-Reference Labs, Canadian Patient Registry Read More »

To access this post, you must purchase The Dark Report.

Comments

;

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.